DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20205544

Evaluation of analgesic activity of levofloxacin in adult albino rats

Prasanna Kumari S., Latha K., Meeradevi A.

Abstract


Background: Levofloxacin is a fluorinated quinolone antimicrobial used in the treatment of various bacterial infections and was active against both gram positive and gram negative bacteria. Levofloxacin is an optically active isomer of ofloxacin. Apart from its antibacterial action, it also exhibit antinociceptive properties. This study was conducted with the aim to evaluate the analgesic activity of Levofloxacin in albino rat in comparison with aspirin.

Methods: Thirty adult albino rats weighing 150-250 gm were obtained from central animal house. The animals were divided into five groups of six animals each. Group I served as control received normal feed and water. Group II served as standard received tablet aspirin 100 mg/kg (oral) and Group III, IV, V served as test T1, T2, T3 and received tablet levofloxacin 10 mg/kg, 20 mg/kg and 40 mg/kg (oral), respectively. The analgesic effect of levofloxacin was evaluated using Eddy’s hot plate and tail flick methods and compared with standard analgesic aspirin. The values obtained were expressed as mean±SD. Statistical analysis of difference between groups were carried out using one-way analysis of variance (ANOVA). Probability p<0.05 was taken as the level of statistical significance.

Results: Levofloxacin at 40 mg/kg showed statistically (p<0.05) elevation in pain threshold and a higher antinociceptive activity in comparison to control and standard groups.

Conclusions: In the present study, levofloxacin has showed promising results as an analgesic when compared to the control and standard groups. It may be a lead compound for identifying newer adjuvant analgesic agents.


Keywords


Analgesic activity, Levofloxacin, Tail flick method, Eddy’s hot plate method

Full Text:

PDF

References


H. Merskey. Pain terms: a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. Pain. 1979;6(3):249-52.

Fields HL, Martin JB. Pain Pathophysiology and management. In: Harrisons Principles of Internal Medicine, 17th edition, Volume I, McGraw-Hill Companies, United States of America. 2007;81-86.

DJ Hewitt, RJ Hargreaves, SP Curtis, D Michelson. Challenges in analgesic drug development. Clinical pharmacology & therapeutics. 2009;86(4):447-50.

GR Hanson, PJ Ventrurelli, AE Fleckenstein, Jones Bartlett, Boston. Mass USA Drugs and society. 10th edition. 2009.

Eddy NB, Leimbach D. Synthetic analgesics. II. Dithienylbutenyl - And dithienylbutylamines. J Pharmacol Exp Ther. 1953;107(3):385-93.

Kulkarni SK. Handbook of Experimental Pharmacology. 3rd ed. New Delhi: Vallabh Prakashan. 1999.

S Higuchi, N Tanaka, Shiioiri Y, Otomos S, Aihara H. Two modes of analgesic action of aspirin, and the site of analgesic action of salicyclic acid. International Journal 0f Tissue Reactions.1986;8(4):327-31.

Medhi B, Prakash A, editors. Practical manual of experimental and clinical pharmacology.1st edition. New Delhi; Jaypee Publications. 2010;322-5.

Vogel H. H.I Central analgesic activity, In vitro methods for opioid activity. Drug Discovery and Evaluation: Pharmacological Assays. Springer-Verlag Berlin Heidelberg New York. 2007;360-65.

Woolfe G, MacDonald AD. The evaluation of analgesic action pethidine hydrochloride. Journal of Pharmacology and Experimental Therapeutics. 1994;80(3):300-07.

Yildiran G, Ulak G, GoÈldeli E, Utkan T, Gacar N, Erden BF. Antinociception induced by verapamil and chloramphenicol in mice. Biol Neonatology. 1997;72:28-31.

Erden BF, Ulak G, Ylldlz F, Utkan T. Antidepressant, anxiogenic and antinociceptive properties of levofloxacin in rats and mice. Pharmacology Biochemistry and Behavior. 2001;68(3):435-41.

Takasuna K, Kasai Y, Usui C, Takahashi M, Hirohashi M, Tamura K, Takayama S. General pharmacology of the new quinolone antibacterial agent, levofloxacin. Arzneimittel for schung. 1992;43(3A):408-18.

Schroeder CI, Doering CJ, Zamponi GW, Lewis RJ. N-type calcium channel blockers: Novel therapeutics for the treatment of pain. Medicinal Chemistry. 2006;2(5):535-43.

Zamponi GW, Lewis RJ, Todorovic SM, Arneric SP, Snutch TP. Role of voltage-gated calcium channels in ascending pain pathways. Brain Res Rev. 2009;60(1):84-9.

Kerr LM, Filloux F, Olivera BM, Jackson H, Wamsley JK. Autoradiographic localization of calcium channels with [125I] omega-conotoxin in rat brain. Eur J Pharmacol. 1988;146(1):181-3.

Erden BF, Ulak G, Yildiz F, Utkan T, Ozdemirci S, Gacar N. Antidepressant, anxiogenic, and antinociceptive properties of levofloxacin in rats and mice. Pharmacology, Biochemistry and Behavior. 2001;68:435-41.

Yaksh TL. Calcium channels as therapeutic targets in neuropathic pain. J Pain. 2006;(1):S13-30.

McGivern JG, McDonough SI. Voltage-gated calcium channels as targets for the treatment of chronic pain. Current Drug Targets CNS Neurological Disorders. 2004;3(6):457-78.

Metterlein T, Schuster F, Tadda L, Hager M, Muldoon S, Capacchione J, et al. Fluoroquinolones influence the intracellular calcium handling in individuals susceptible to malignant hyperthermia. Muscle nerve. 2011;44(2):208-12.

Gohil K, Bell JR, Ramachandran J, Miljanich GP. Neuroanatomical distribution of receptors for a novel voltagesensitive calcium-channel antagonist, SNX-230 (omegaconopeptide MVIIC). Brain Res. 1994;653(1-2):258-66.